Evidence map›Paper›PMID 40266528›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Dendritic Cell Cancer Vaccines: Clinical Production for Cancer Immunotherapy.

Hoyoung M Maeng, Purevdorj B Olkhanud, Mary Black, Steve L Highfill, David F Stroncek, Jay A Berzofsky

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hoyoung M MaengVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. hoyoung.maeng@nih.gov.
Purevdorj B OlkhanudVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mary BlackCenter for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA.
Steve L HighfillCenter for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA.
David F StroncekCenter for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA.
Jay A BerzofskyVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cell (DC) cancer vaccines are used to circumvent the problem that DCs in patients with cancer usually do not mature properly in the cancer environment. Peripheral DCs are fewer in number and hard to isolate cleanly. Instead, autologous DCs can be matured from monocyte precursors obtained by apheresis and elutriation from peripheral blood. Here, we describe procedures for harvesting cells, growing them into DCs, inducing antigen expression by pulsing them with antigenic peptides or inducing antigen expression by transducing them with antigens expressed by a recombinant adenovirus (or other viral vector), maturing them in vitro, and then administering them to patients.

Indexed as

Cancer VaccinesDendritic CellsImmunotherapyNeoplasmsAdenoviridaeAntigens, NeoplasmHumansAntigens, NeoplasmCancer VaccinesCancer immunotherapyCancer vaccinesClinical trialsDendritic cells

Identifiers

PMID40266528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.